McKetin, Rebecca http://orcid.org/0000-0003-2833-4830
Degan, Tayla J.
Saunders, Lucy
Nguyen, Long
Dore, Gregory
Shoptaw, Steven
Farrell, Michael
Degenhardt, Louisa
Kelly, Peter J.
Turner, Alyna
Clare, Philip J.
Dean, Olivia M.
Arunogiri, Shalini
Colledge-Frisby, Samantha
Koeijers, Juanita
Goodman-Meza, David
Sinclair, Barbara
Reid, David
Hill, Harry
Hayllar, Jeremy
Christmass, Michael
Cordaro, Frank
Lundin, Robert
Liaw, Willy
Liu, Danica
Holyoak, Ellie
Wu, Brian Tid-Fung
Keygan, Joel
Kontogiannis, Ava
Palmer, Lily
Morrison, Caity
Wrobel, Anna
Hyland, Bec
Byrne, Marianne
Russell, Samantha
Zahra, Emma
Berk, Michael
Funding for this research was provided by:
Medical Research Future Fund (2007155)
Article History
Received: 1 March 2024
Accepted: 10 June 2024
First Online: 22 June 2024
Declarations
:
: This trial has been approved by the Joint University of Wollongong and Illawarra Shoalhaven Local Health District Health Medical Human Research Ethics Committee (2021/ETH12037), and the North Metropolitan Area Mental Health Services Human Research Ethics Committee (PRN RGS0000005312). All participants provide informed consent prior to participation.
: All participants provide informed consent which includes consent to publish the data in a way that they cannot be identified. The participant information sheet and informed consent form are available from the authors on request.
: MB has received grants from Meat and Livestock Board, Woolworths, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier; received speaker support from Lundbeck, Controversias Barcelona, Servier, Medisquire, Janssen, Medplan, Abbott India, Sandoz, Astra Zeneca Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Pfizer, Sanofi-Synthelabo Solvay, and Wyeth; and, consulted to Milken Institute AstraZeneca Bristol Myers Squibb Eli Lilly Bioadvantex Merck Glaxo SmithKline Lundbeck Janssen Cilag Servier. LD has received untied educational grants for the study of new opioid medications in Australia from Indivior and Seqirus. MF has received unrestricted educational grants for studies of opioid medications in Australia from Indivior, Mundipharma and Seqirus. OD has received grant support from Lilly and Servier, and in-kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. SA has received speaker support from Camurus, Gilead, Janssen and Servier. Other authors have no competing interests.